FDA aims to decide on ISTA's once-daily eye drug by mid-October

03/8/2010 | Google

The FDA set Oct. 16 as its approval deadline for ISTA Pharmaceuticals' XiDay, a once-daily formulation of eye drug Xibrom. Both drugs are indicated for eye inflammation after cataract surgery.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC